RetroClipArt / Shutterstock.com
There is no uniform interpretation of the scope of the Bolar exemption in Europe, but a CJEU opinion harmonising the issue may be on the way, says Rafal Witek.
In recent months, we’ve had the opportunity to analyse the final decisions of the courts in Poland and Germany on the Astellas v Polpharma case interpreting the range of the Bolar exemption in Europe (for earlier details of the case click here).
In the case, Polish company Zakłady Farmaceutyczne Polpharma SA (Polpharma) produced an active pharmaceutical ingredient (API) which it offered it to other companies, and in particular to a German company Hexal AG, claiming the API was being offered only to allow them to carry out whatever activities were necessary to obtain marketing approval (MA) for a generic product.
The plaintiff, Astellas Pharma Inc, sued Polpharma for infringing its German and Polish patents protecting the API offered by Polpharma. Polpharma argued that its activities did not infringe Astellas’ patent because they were covered by the Bolar exemption defined in both Polish law (Article 69.1.[iv] IPL) and German law (§11 Nr. 2b PatG).
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Bolar, CJEU, patented substances, patent infringement